Moreover, the 36-month beta value for BHC is 0.34. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BHC is 291.56M and currently, short sellers hold a 3.09% of that float. On April 30, 2025, BHC’s average trading volume was 2.62M shares.
BHC) stock’s latest price update
The stock price of Bausch Health Companies Inc (NYSE: BHC) has plunged by -5.54 when compared to previous closing price of 5.51, but the company has seen a 0.68% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-29 that A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted medical device license clearance for Thermage® FLX, the latest generation of the globally-recognized Thermage® system for non-invasive skin tightening and contouring. “The clearance of Thermage FLX in Canada is a positive development for our company and important for the continued growth of our aesthetic business”, said Thomas J.
BHC’s Market Performance
Bausch Health Companies Inc (BHC) has seen a 0.68% rise in stock performance for the week, with a -19.55% decline in the past month and a -30.32% plunge in the past quarter. The volatility ratio for the week is 3.97%, and the volatility levels for the past 30 days are at 7.58% for BHC. The simple moving average for the last 20 days is 2.59% for BHC stock, with a simple moving average of -26.84% for the last 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Piper Sandler repeating the rating for BHC by listing it as a “Underweight.” The predicted price for BHC in the upcoming period, according to Piper Sandler is $3 based on the research report published on August 02, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see BHC reach a price target of $8. The rating they have provided for BHC stocks is “Mkt Perform” according to the report published on July 10th, 2024.
Jefferies gave a rating of “Buy” to BHC, setting the target price at $16 in the report published on September 20th of the previous year.
BHC Trading at -16.82% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.16% of loss for the given period.
Volatility was left at 7.58%, however, over the last 30 days, the volatility rate increased by 3.97%, as shares sank -17.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.63% lower at present.
During the last 5 trading sessions, BHC rose by +0.10%, which changed the moving average for the period of 200-days by -30.26% in comparison to the 20-day moving average, which settled at $5.07. In addition, Bausch Health Companies Inc saw -35.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Carson Seana, who sale 440 shares at the price of $8.35 back on Dec 02 ’24. After this action, Carson Seana now owns 433,066 shares of Bausch Health Companies Inc, valued at $3,674 using the latest closing price.
Carson Seana, the Officer of Bausch Health Companies Inc, proposed sale 440 shares at $8.35 during a trade that took place back on Dec 02 ’24, which means that Carson Seana is holding shares at $3,674 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.63 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.0. The total capital return value is set at 0.08.
Based on Bausch Health Companies Inc (BHC), the company’s capital structure generated 1.06 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at -16.9. The interest coverage ratio of the stock is 1.15.
Currently, EBITDA for the company is 1.55 billion with net debt to EBITDA at 7.23. When we switch over and look at the enterprise to sales, we see a ratio of 2.33. The receivables turnover for the company is 4.49for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To wrap up, the performance of Bausch Health Companies Inc (BHC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
